文献速递白血病

尼洛替尼治疗儿童费城染色体阳性慢性髓系白血病二期研究

Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia.
PubMed 文献 · Blood · 2019-01-01

耐药/不耐受组第6周期主要分子学反应(MMR)率为39.4%,新诊断组第12周期MMR率和完全细胞遗传学反应(CCyR)率均为64.0%。尼洛替尼在儿童中安全性总体与成人已知特征相当,未发现新安全性信号。

要点

  • 耐药/不耐受组第6周期MMR率39.4%,24周期内57.6%达到或维持MMR。
  • 新诊断组第12周期MMR率和CCyR率均为64.0%,24周期累积MMR率68.0%。
  • 儿童安全性总体与成人相当,未观察到心血管事件,肝脏实验室异常更常见。

核心结论

  • 尼洛替尼在Ph+ CML-CP儿童患者中显示出疗效且安全性可控。

研究设计与样本

  • 数据分析时最短随访至24个周期,每周期28天。

主要发现

  • 耐药/不耐受组第6周期MMR率为39.4%(主要终点),24周期内57.6%达到或维持MMR、81.8%达到或维持CCyR。
  • 新诊断组第12周期MMR率和CCyR率均为64.0%(主要终点),24周期累积MMR率和CCyR率分别为68.0%和84.0%。
  • 儿童安全性总体与成人已知特征相当,未观察到心血管事件,肝脏实验室异常更频繁,未发现新安全性信号。

关键数值与推荐

  • 耐药/不耐受组主要终点为第6周期MMR率39.4%。
  • 新诊断组主要终点为第12周期MMR率64.0%和第12周期CCyR率64.0%。

临床怎么用

  • 尼洛替尼可作为Ph+ CML-CP儿童患者对伊马替尼耐药或不耐受时的治疗选择。
  • 治疗中需关注肝脏实验室异常,心血管事件在本研究未观察到。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic myeloid leukemia (CML) is rare in children and accounts for ≤15% of all myeloid leukemia cases. When we initiated this study with nilotinib, imatinib was the only tyrosine kinase inhibitor indicated for pediatric patients with Philadelphia chromosome-positive (Ph+) CML in chronic phase (CP); alternative treatment options were needed, particularly for patients who developed resistance or intolerance (R/I) to imatinib. This phase 2 study enrolled pediatric patients with either Ph+ CML-CP R/I to imatinib or dasatinib or newly diagnosed Ph+ CML-CP. Data presented are from analyses with minimum follow-up of up to 24 cycles (1 cycle is 28 days). Fifty-nine patients with Ph+ CML-CP were enrolled, and 58 were treated (R/I, n = 33; newly diagnosed, n = 25). Major molecular response (MMR) rate at cycle 6 in the R/I cohort was 39.4% (primary end point); 57.6% of patients achieved or maintained MMR and 81.8% achieved or maintained complete cytogenetic response (CCyR) by 24 cycles. In patients with newly diagnosed disease, rates of MMR by cycle 12 and CCyR at cycle 12 were 64.0% each (primary end points); by cycle 24, cumulative MMR and CCyR rates were 68.0% and 84.0%, respectively. The safety profile of nilotinib in pediatric patients was generally comparable with the known safety profile in adults, although cardiovascular events were not observed in this study, and hepatic laboratory abnormalities were more frequent; no new safety signals were identified. In summary, nilotinib demonstrated efficacy and a manageable safety profile in pediatric patients with Ph+ CML-CP. This trial was registered at www.clinicaltrials.gov as #NCT01844765.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Hijiya N, Maschan A, Rizzari C, et al. Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia. Blood. 2019. PMID: 31511239. doi:10.1182/blood.2019000069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。